Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: A case report

Immunotherapy

Volumn 7, Issue 8, 2015, Pages 855-860

  Schirrmacher, Volker ^a   Stücker, Wilfried ^a   Lulei, Maria ^a   Bihari, Akos Sigmund ^a   Sprenger, Tobias ^a  

^a Center of Immunology and Oncology (IOZK)   (Germany)

Author keywords

breast cancer; dendritic cell vaccination; hyperthermia; immunotherapy; Newcastle disease virus

Indexed keywords

DENDRITIC CELL VACCINE; FLUORODEOXYGLUCOSE F 18; HORMONE RECEPTOR; ONCOLYTIC PARAMYXOVIRUS;

AGED; ARTICLE; BODY TEMPERATURE; BREAST CANCER; CANCER GROWTH; CANCER IMMUNIZATION; CANCER PATIENT; CANCER SURVIVAL; CASE REPORT; CELL LYSATE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTHERMIA; IMMUNE RESPONSE; LIVER BIOPSY; LIVER METASTASIS; LONG TERM SURVIVAL; MEMORY T LYMPHOCYTE; ONCO HYPERTHERMIA DEVICE; ONCOLYTIC VIROTHERAPY; OUTCOME ASSESSMENT; PATIENT HISTORY OF MASTECTOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOFREQUENCY HYPERTHERMIA; STAGING; BREAST NEOPLASMS; IMMUNOTHERAPY; LIVER NEOPLASMS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; SECONDARY; SURVIVOR; TREATMENT OUTCOME;

AGED; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; ONCOLYTIC VIROTHERAPY; QUALITY OF LIFE; SURVIVORS; TREATMENT OUTCOME;

EID: 84942095178     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.48     Document Type: Article

References (26)

1. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Krebs in Deutschland 2009/2010 (9th Edition). Robert Koch Institute, Berlin, Germany (2013).
2. Atalay G, Biganzoli L, Renard F et al. EORTC Breast Cancer and Early Clinical Studies Groups. Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: A retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur. J. Cancer 39(17), 2439-2449 (2003).
3. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. www.awmf.org
4. Curigliano G, Criscitiello C, Esposito A et al. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium. Breast 22(Suppl. 2), S96-S99 (2013).
5. Gelao L, Criscitiello C, Esposito A et al. Dendritic cellbased vaccines: clinical applications in breast cancer. Immunotherapy 6(3), 349-360 (2014).
6. Fournier P, Schirrmacher V. Oncolytic Newcastle disease virus as cutting edge between tumor and host. Biology (Basel) 2(3), 936-975 (2013).
7. Frey B, Weiss EM, Rubner Y et al. Old and new facts about hyperthermia-induced modulations of the immune system. Int. J. Hyperthermia 28(6), 528-542 (2012).
8. Hildebrandt B, Wust P, Ahlers O et al. The cellular and molecular basis of hyperthermia. Crit. Rev. Oncol. Hematol. 43, 33-56 (2002).
9. Schirrmacher V, Bihari AS, Stücker W, Sprenger T. Longterm remission of prostate cancer with extensive bone metastases upon immuno-and virotherapy: A case report. Oncol. Lett. 8(6), 2403-2406 (2014).
10. Zaslavsky E, Hershberg U, Seto J et al. Antiviral response dictated by choreographed cascade of transcription factors. J. Immunol. 184, 2908-2917 (2010).
11. transcription factors causing upregulation of 779 genes.
12. Burnet FM. The concept of immunological surveillance. Prog. Exp. Tumor Res. 13, 1-27 (1970).
13. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329-360 (2004).
14. Mahmoud SM, Paish EC, Powe DG et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J. Clin. Oncol. 29(15), 1949-1955 (2011).
15. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 9(4), 212 (2007).
16. Schirrmacher V, Feuerer M, Beckhove P, Ahlert T, Umansky V. T cell memory, anergy and immunotherapy in breast cancer. J. Mammary Gland Biol. Neoplasia 7, 201-208 (2002).
17. Feuerer M, Rocha M, Bai L et al. Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. Int. J. Cancer 92, 96-105 (2001).
18. Sommerfeld N, Schütz F, Sohn C et al. The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res. 66, 8258-8265 (2006).
19. Feuerer M, Beckhove P, Bai L et al. Therapy of human tumors in NOD/SCID mice with patient derived reactivated memory T cells from bone marrow. Nat. Med. 7, 452-458 (2001).
20. Ahlert T, Sauerbrei W, Bastert G et al. Tumor cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines. J. Clin. Oncol. 15, 1354-1366 (1997).
21. Chang E, Chalikonda S, Friedl J et al. Targeting vaccinia to solid tumors with local hyperthermia. Hum. Gene Ther. 16, 435-444 (2005).
22. Eisenberg DP, Carpenter SG, Adusumilli PS et al. Hyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway. Surgery 148, 325-334 (2010).
23. Knippertz I, Stein MF, Dörrie J et al. Mild hyperthermia enhances human monocyte derived dendritic cell functions and offers potential for applications in vaccination strategies. Int. J. Hyperthermia 27, 591-603 (2011).
24. Hou W, Zhang Q, Yan Z et al. Strange attractors: DAMPs and autophagy link tumor cell death and immunity. Cell Death Dis. 4, e966 (2013).
25. Bai L, Koopmann J, Fiola C et al. Dendritic cells pulsed with viral oncolysate potently stimulate autologous T cells from cancer patients. Int. J. Oncol. 21(4), 685-694 (2002).
26. Mitchell DA, Batich KA, Gunn MD et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519(7543), 366-369 (2015).